Baseline Demographic and Clinical Characteristics
| Variable | Baseline data |
| Mean age (y) | 68 (range, 52–78) |
| Sex (n) | |
| Male | 22 (69%) |
| Female | 10 (31%) |
| Lymphoma status (n) | |
| Relapsed | 17 (53%) |
| Refractory | 15 (47%) |
| MIPI (n) | |
| ≤3 (low risk) | 17 (53%) |
| 4–5 (intermediate risk) | 9 (28%) |
| ≥6 (high risk) | 6 (19%) |
| Mean MIPI ± SD | 3.78 ± 1.60 |
| Presence of B symptoms (n) | 7 (22%) |
| Previous cancer surgery (n) | 8 (25%) |
| Previous radiation therapy (n) | 6 (19%) |
| Previous chemotherapy (n) | |
| Prior rituximab | 32 (100%) |
| Prior alkylator | 31 (97%) |
| Response to the most recent rituximab-based chemotherapy (n) | |
| Complete | 16 (50%) |
| Partial | 6 (19%) |
| Stable disease | 4 (13%) |
| Progressive disease | 5 (16%) |
| Not available | 1 (3%) |
| Cyclin D1 status (n) | |
| Positive | 17 (53%) |
| Negative | 8 (25%) |
| Not available | 7 (22%) |
| LDH level (n) | |
| <250 IU/L | 20 (63%) |
| 250–450 IU/L (reference range) | 4 (13%) |
| >450 IU/L | 7 (22%) |
| Not available | 1 (3%) |
| β2-microglobulin level (n) | |
| 1.1–2.8 mg/L (reference range) | 31 (97%) |
| >2.8 mg/L | 1 (3%) |
LDH = lactate dehydrogenase.